Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993952022> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1993952022 abstract "Triple negative breast cancer (TNBC), a subpopulation of breast cancer that has a high mortality rate, recently has been shown to be quite diverse with approximately 7 different molecular subtypes. As a result, treatment with an agent that can potentially target multiple pathways might be an effective approach. Zyflamend (Zy), a unique herbal preparation consisting of 10 concentrated herbal extracts, has been shown to suppress the proliferation of various cancer cells including prostate, melanoma, and bladder cancers. However, its role in TNBC has not been investigated. To examine its anticancer activity in TNBC, we utilized a crystal violet staining assay to determine the proliferation of cells, FACS analysis for cell cycle and apoptosis and gene/protein expression analysis to delineate the plausible mechanism of action. Among a number of breast cancer cell lines including MCF-7, SUM149, MDMB231, BT549 and HCC1937, Zy exerted stronger inhibitory effect in all TNBC cells with IC50 values ranging between 400-800μg/ml (0.5-1 μl/ml) whereas MCF-7, an estrogen/progesterone receptor positive cell line, required 1000μg/ml (1.5μl/ml). Similarly, the morphologies of SUM149, MDAMB231, and BT549 cell lines were notably disrupted by Zy treatment (400μg/ml) when these cells were cultured using three dimensional techniques. FACS analysis showed that there was a dramatic shift to subG1 phase, suggesting cells might undergo apoptosis. Reverse Phase Proteomic Array indicated that proteins affecting the cell cycle progression, cell junction regulation, and cell signaling were altered in BT549 and HCC1937 by 24 hr Zy treatment (800μg/ml).. When compared to the vehicle control, gene expression analysis showed that several inflammatory genes were downregulated by at least 50% and these included 5- and 12-lipooxygenase, leukotriene receptors, TNF receptor, and NF-κB in HCC1937 (800μg/ml), MDAMB231(800μg/ml) and SUM149 (400μg/ml) cells. Taken together, our preliminary data suggests that Zy inhibits TNBC proliferation by inhibiting inflammation, regulating cell cycle, and inducing cell death. Further studies are ongoing to evaluate these effects in in vivo triple negative breast cancer models. Citation Format: Angelica M. Gutierrez-Barrera, Banu K. Arun, Peiying Yang, Carrie Cartwright. Zyflamend, a multi-herbal product, selectively inhibits the growth of triple negative breast cancer cells in vitro . [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3218. doi:10.1158/1538-7445.AM2014-3218" @default.
- W1993952022 created "2016-06-24" @default.
- W1993952022 creator A5003693436 @default.
- W1993952022 creator A5005148722 @default.
- W1993952022 creator A5015127974 @default.
- W1993952022 creator A5091254705 @default.
- W1993952022 date "2014-09-30" @default.
- W1993952022 modified "2023-09-24" @default.
- W1993952022 title "Abstract 3218: Zyflamend, a multi-herbal product, selectively inhibits the growth of triple negative breast cancer cellsin vitro" @default.
- W1993952022 doi "https://doi.org/10.1158/1538-7445.am2014-3218" @default.
- W1993952022 hasPublicationYear "2014" @default.
- W1993952022 type Work @default.
- W1993952022 sameAs 1993952022 @default.
- W1993952022 citedByCount "0" @default.
- W1993952022 crossrefType "proceedings-article" @default.
- W1993952022 hasAuthorship W1993952022A5003693436 @default.
- W1993952022 hasAuthorship W1993952022A5005148722 @default.
- W1993952022 hasAuthorship W1993952022A5015127974 @default.
- W1993952022 hasAuthorship W1993952022A5091254705 @default.
- W1993952022 hasConcept C121608353 @default.
- W1993952022 hasConcept C126322002 @default.
- W1993952022 hasConcept C1491633281 @default.
- W1993952022 hasConcept C185592680 @default.
- W1993952022 hasConcept C190283241 @default.
- W1993952022 hasConcept C2780110267 @default.
- W1993952022 hasConcept C29537977 @default.
- W1993952022 hasConcept C502942594 @default.
- W1993952022 hasConcept C530470458 @default.
- W1993952022 hasConcept C54355233 @default.
- W1993952022 hasConcept C55493867 @default.
- W1993952022 hasConcept C62112901 @default.
- W1993952022 hasConcept C71924100 @default.
- W1993952022 hasConcept C81885089 @default.
- W1993952022 hasConcept C86803240 @default.
- W1993952022 hasConcept C96232424 @default.
- W1993952022 hasConceptScore W1993952022C121608353 @default.
- W1993952022 hasConceptScore W1993952022C126322002 @default.
- W1993952022 hasConceptScore W1993952022C1491633281 @default.
- W1993952022 hasConceptScore W1993952022C185592680 @default.
- W1993952022 hasConceptScore W1993952022C190283241 @default.
- W1993952022 hasConceptScore W1993952022C2780110267 @default.
- W1993952022 hasConceptScore W1993952022C29537977 @default.
- W1993952022 hasConceptScore W1993952022C502942594 @default.
- W1993952022 hasConceptScore W1993952022C530470458 @default.
- W1993952022 hasConceptScore W1993952022C54355233 @default.
- W1993952022 hasConceptScore W1993952022C55493867 @default.
- W1993952022 hasConceptScore W1993952022C62112901 @default.
- W1993952022 hasConceptScore W1993952022C71924100 @default.
- W1993952022 hasConceptScore W1993952022C81885089 @default.
- W1993952022 hasConceptScore W1993952022C86803240 @default.
- W1993952022 hasConceptScore W1993952022C96232424 @default.
- W1993952022 hasLocation W19939520221 @default.
- W1993952022 hasOpenAccess W1993952022 @default.
- W1993952022 hasPrimaryLocation W19939520221 @default.
- W1993952022 hasRelatedWork W1965483363 @default.
- W1993952022 hasRelatedWork W1971231891 @default.
- W1993952022 hasRelatedWork W2014557851 @default.
- W1993952022 hasRelatedWork W2037208002 @default.
- W1993952022 hasRelatedWork W2059831422 @default.
- W1993952022 hasRelatedWork W2394850978 @default.
- W1993952022 hasRelatedWork W2477201797 @default.
- W1993952022 hasRelatedWork W2520959410 @default.
- W1993952022 hasRelatedWork W2523880107 @default.
- W1993952022 hasRelatedWork W2611060679 @default.
- W1993952022 hasRelatedWork W2758279811 @default.
- W1993952022 hasRelatedWork W2795144797 @default.
- W1993952022 hasRelatedWork W2890139082 @default.
- W1993952022 hasRelatedWork W2984171582 @default.
- W1993952022 hasRelatedWork W3035225879 @default.
- W1993952022 hasRelatedWork W3038822001 @default.
- W1993952022 hasRelatedWork W3039024314 @default.
- W1993952022 hasRelatedWork W3108709169 @default.
- W1993952022 hasRelatedWork W3129346088 @default.
- W1993952022 hasRelatedWork W3184795446 @default.
- W1993952022 isParatext "false" @default.
- W1993952022 isRetracted "false" @default.
- W1993952022 magId "1993952022" @default.
- W1993952022 workType "article" @default.